Christopher Anzalone
Vermögen: 321 Mio $ am 31.07.2026
Vermögen: 321 Mio $ am 31.07.2026
Christopher Richard Anzalone ist ein Geschäftsmann, der die Benet Group LLC und Nanotope, Inc. gegründet hat und der 5 verschiedene Unternehmen geleitet hat. Derzeit ist er President, Chief Executive Officer & Director bei Arrowhead Pharmaceuticals, Inc. und Chairman & Chief Executive Officer von Calando Pharmaceuticals, Inc. (eine Tochtergesellschaft von Arrowhead Pharmaceuticals, Inc.). Dr. Anzalone ist außerdem im Vorstand von 5 weiteren Unternehmen. In seiner früheren Laufbahn war Dr. Anzalone Chief Executive Officer bei NanoInk, Inc., Partner bei Galway Partners LLC, Präsident, Chief Executive Officer & Director bei Nanotope, Inc. und Chief Executive Officer bei Benet Group LLC. Christopher Richard Anzalone promovierte an der University of California, Los Angeles, und erwarb einen Bachelor-Abschluss an der Lawrence University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.01.2026 | 3’792’739 ( 2.69% ) | 321 Mio $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 01.12.2007 |
Ablaris Therapeutics, Inc. | Direktor/Vorstandsmitglied | - |
Tego Biosciences Corp. | Direktor/Vorstandsmitglied | - |
Arrowhead Madison, Inc. | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
NanoInk, Inc.
NanoInk, Inc. Industrial MachineryProducer Manufacturing Manufactures nanolithography tools and other nanoscale devices | Präsident | 01.01.2004 |
Galway Partners LLC
Galway Partners LLC Investment ManagersFinance Acts as an alternative investment manager | Corporate Officer/Principal | 01.01.2003 |
| KRONOS BIO, INC. | Direktor/Vorstandsmitglied | - |
| VIR BIOTECHNOLOGY, INC. | Direktor/Vorstandsmitglied | - |
Roche Madison, Inc.
Roche Madison, Inc. Pharmaceuticals: MajorHealth Technology Provides gene transfer technologies to the pharmaceutical industry | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 15 |
|---|---|
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drugs to treat intractable diseases | Health Technology |
NanoInk, Inc.
NanoInk, Inc. Industrial MachineryProducer Manufacturing Manufactures nanolithography tools and other nanoscale devices | Producer Manufacturing |
Calando Pharmaceuticals, Inc.
Calando Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in the design and development of drug-delivery-enhanced small molecule therapeutics | Health Technology |
Nanotope, Inc.
Nanotope, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lawrence University
Lawrence University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Madison, Inc.
Roche Madison, Inc. Pharmaceuticals: MajorHealth Technology Provides gene transfer technologies to the pharmaceutical industry | Health Technology |
Unidym, Inc.
Unidym, Inc. Electronic Production EquipmentElectronic Technology Develops and manufactures carbon nanotubes | Electronic Technology |
Benet Group LLC
Benet Group LLC Financial ConglomeratesFinance Private equity firm | Finance |
Galway Partners LLC
Galway Partners LLC Investment ManagersFinance Acts as an alternative investment manager | Finance |
Ablaris Therapeutics, Inc. | |
Tego Biosciences Corp. | |
Arrowhead Madison, Inc. | |
Vir Biotechnology, Inc.
Vir Biotechnology, Inc. BiotechnologyHealth Technology Develops cures and treatments drug for viral & bacterial diseases | Health Technology |
Kronos Bio, Inc.
Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen